Biotech CMO-CEO Fireside Discussion on Working Through Challenges

Alise Reicin, MD, is a 20+ year R&D veteran of the pharmaceutical industry and served most recently as President of Global Clinical Development at Celgene. In her distinguished career at Merck, EMD Serono and Celgene, Dr Reicin led teams and functions that enabled the approval of >15 novel drugs and indications that now account for over $20B in global sales across a variety of disease areas including autoimmune (Zeposia®, Arcoxia®, Mavenclad®, Simponi®) and oncology (Keytruda®, Inrebic®, Reblozyl®, Bavencio®, Breyanzi®). She joined Tectonic in 2020 as President and CEO and holds an MD with honors from Harvard Medical School where she was part of the Health Science and Technology program (HST). Dr Reici served as a faculty member at Columbia University’s Medical School for a decade, where she did research and specialized in the treatment of infectious diseases.

Marcie is currently the Chief Medical Officer at Tectonic Therapeutic, Watertown MA. She has over 18 years of experience in drug development across all stages of clinical drug development from translational/early development through post approval and across multiple modalities including small molecules, siRNA and biologics. She was named one of the 2023 Top Women in BioPharma by Endpoints News. Prior to joining Tectonic, she was VP and Head of Clinical Development for the Immunology/Inflammation Therapeutic Area at Regeneron Pharmaceuticals. In that role she led the clinical development of Dupixent® through over nine Phase 3 trial initiations and multiple regulatory approvals globally, including approvals for adult and pediatric asthma, pediatric AD, chronic rhinosinusitis with nasal polyps. She was instrumental in the pivotal study design and its execution supporting the recent approval in eosinophilic esophagitis and design of COPD studies. Over her career, which has included time at Merck and Alnylam and EMD Serono, she has built and led clinical development and cross functional groups across a range of therapeutic areas including respiratory, inflammation, bone, anemia and metabolic and rare diseases. Prior to entry into drug development, Marcie held a staff position in the Pulmonary Unit at Massachusetts General Hospital/Harvard Medical School where she founded and directed the Adult Cystic Fibrosis Program. She holds an AB from Princeton University and a MD/ MS from Washington University, St. Louis and completed her internal medicine and pulmonary fellowship training at Harvard Medical School affiliated hospitals.